Regulation on Health Technology Assessment

The Regulation on Health Technology Assessment (HTAR) was proposed by the European Commission in 2018. It was formally adopted in December 2021 and will apply from January 2025.

2023 winners

Publication of EHA Annual General Meeting 2024 minutes

The 2024 EHA Annual General Meeting (AGM) took place in the vibrant city of Madrid, Spain, on June 14, 2024. Scheduled on Friday during the EHA Annual Congress, the meeting was once more in a hybrid format.

Highlights from the SWG

Session on thrombocytopenias and platelet function disordersFull title‘Thrombocytopenias and platelet function disorders: Recent developments and perspectives in immune thrombocytopenia. ’

DateThe session took place as part of the EHA 2023 Congress. This was held from June 8–11, 2023.

SWG Educational Activities

MeetingsSession on thrombocytopenias and platelet function disordersAt the EHA 2023 Congress, we held a session on ‘Thrombocytopenias and platelet function disorders: Recent developments and perspectives in immune thrombocytopenia.

Tools and Overview Tables

EHA2023 session on COVID-19 and influenzaThe SWG suggested the above session, which was held during the EHA 2023 Hybrid Congress. Full titleCOVID-19 and influenza in patients with hematological malignancies.

SWG Educational Activities

Social and public EHA-related activitiesX/Twitter accountThe SWG on Infections in Hematology has an account on X (formerly known as Twitter). Our name on X is @EHAInfectionsH1.

Highlights from the SWG

Impactful activitiesGuideline development projectThe most relevant and impactful activities of the SWG include those related to the guideline development project. There were regular meetings with the Guidelines Expert Panel Committee.

Publications

The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review
Salek, S. ; Ionova, T. ; Oliva, E. N. ; Andreas, M. ; Skoetz, N. ; Kreuzberger, N. ; Laane, E.

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.